Vimarsana
Biggest News Aggregation in the World

Page 11 - Otonomy Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Otonomy Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Otonomy Inc Today - Breaking & Trending Today

-$0.19 EPS Expected for Otonomy, Inc. (NASDAQ:OTIC) This Quarter - Vimarsana News

-$0.19 EPS Expected for Otonomy, Inc. (NASDAQ:OTIC) This Quarter

Analysts expect Otonomy, Inc. (NASDAQ:OTIC – Get Rating) to announce earnings per share (EPS) of ($0.19) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Otonomy’s earnings, with estimates ranging from ($0.23) to ($0.17). Otonomy posted earnings of ($0.23) per share in the same quarter last year, which would suggest a […]

Squarepoint Ops LLC Sells 33,456 Shares of Otonomy, Inc. (NASDAQ:OTIC) - Vimarsana News

Squarepoint Ops LLC Sells 33,456 Shares of Otonomy, Inc. (NASDAQ:OTIC)

Squarepoint Ops LLC decreased its holdings in Otonomy, Inc. (NASDAQ:OTIC – Get Rating) by 56.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,230 shares of the biopharmaceutical company’s stock after selling 33,456 shares during the period. Squarepoint Ops LLC’s holdings […]

Otonomy to Host Virtual Investor R&D Event on March 22, 2022 - Vimarsana News

Otonomy to Host Virtual Investor R&D Event on March 22, 2022

15.03.2022 - SAN DIEGO, March 15, 2022 (GLOBE NEWSWIRE) - Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it will host a virtual Investor R&D Event from 10 ...

Otonomy (NASDAQ:OTIC) Stock Rating Lowered by Zacks Investment Research - Vimarsana News

Otonomy (NASDAQ:OTIC) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research downgraded shares of Otonomy (NASDAQ:OTIC – Get Rating) from a buy rating to a hold rating in a report released on Friday morning, Zacks.com reports. According to Zacks, “Otonomy, Inc. engages in developing and commercializing therapeutics to address unmet medical needs in the otology market. It develops therapeutics for treatment of inner […]

Zogenix : Amendment to Annual Report (Form 10-K/A) - Vimarsana News

Zogenix : Amendment to Annual Report (Form 10-K/A)

10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM ... | March 7, 2022